<![CDATA[熊言熊语]]>
2025-06-10T08:06:56Z
思考问题的熊
https://static.quail.ink/media/14rlwa9l.webp
https://static.quail.ink/media/14rlwa9l.webp
https://https://newsletter.kaopubear.top
Quaily
<![CDATA[V028.焦虑的反面是具体：用3年AI实践和你分享这份AI科研心得指南]]>
https://newsletter.kaopubear.top/p/ai-experience#10769
思考问题的熊
2025-06-10T08:06:56Z
2025-06-10T08:06:56Z
<![CDATA[V027.熊言熊语：因为AI 终于我可以尝试把自己最好的东西给你]]>
https://newsletter.kaopubear.top/p/v027-bear-words-because-ai-finally-i-can-share-my-best#8344
思考问题的熊
2025-03-08T08:44:41Z
2025-03-08T08:44:41Z
<![CDATA[V026.熊言熊语：肠癌多篇重要研究发表，以及被忽视的肿瘤DNA甲基化特征之PMD(part2)]]>
https://newsletter.kaopubear.top/p/v026-bear-talk-colon-cancer-important-research-pmd-part2#8343
思考问题的熊
2025-03-08T08:44:28Z
2025-03-08T08:44:28Z
<![CDATA[V025.熊言熊语：详谈 Guardant Shield FDA 获批背后你该了解的那些事]]>
https://newsletter.kaopubear.top/p/v025-bear-talk-guardant-shield-fda-approval#8342
思考问题的熊
2025-03-08T08:44:05Z
2025-03-08T08:44:05Z
<![CDATA[V024.熊言熊语：被忽视的肿瘤DNA甲基化特征PMD（part1）]]>
https://newsletter.kaopubear.top/p/v024-bear-talk-ignored-tumor-dna-methylation-features-pmd-part1#8341
思考问题的熊
2025-03-08T08:43:54Z
2025-03-08T08:43:54Z
<![CDATA[V023.熊言熊语：断网半年后我的思考感悟和秘密项目]]>
https://newsletter.kaopubear.top/p/v023-bear-sayings-reflections-and-secret-projects-after-six-months-offline#8340
思考问题的熊
2025-03-08T08:43:49Z
2025-03-08T08:43:49Z
<![CDATA[V022.熊言熊语：当泛癌早筛领头羊GRAIL也开始卷伴随诊断研究，我们能学到什么]]>
https://newsletter.kaopubear.top/p/v022-bear-talks-when-grail-leader-in-onco-screening-starts-in-companion-diagnostic-research-what-can-we-learn#8339
思考问题的熊
2025-03-08T08:43:32Z
2025-03-08T08:43:32Z
<![CDATA[V021.熊言熊语：引进国外癌症检测产品究竟多贵 & 2023 肿瘤 ctDNA MRD 领域二三事]]>
https://newsletter.kaopubear.top/p/v021-bear-talk-introducing-foreign-cancer-detection-products-cost-2023-tumor-ctdna-mrd#8338
思考问题的熊
2025-03-08T08:43:25Z
2025-03-08T08:43:25Z
<![CDATA[V020.熊言熊语：2023 ESMO 我眼中那些值得关注的 MRD 研究]]>
https://newsletter.kaopubear.top/p/v020-bear-talk-2023-esmo-mrd-research-to-watch#8337
思考问题的熊
2025-03-08T08:43:16Z
2025-03-08T08:43:16Z
<![CDATA[Bonus.熊言熊语茶话会第二期邀请：聊聊工作]]>
https://newsletter.kaopubear.top/p/bonus-bear-talk-tea-party-episode-2-discuss-work#8336
思考问题的熊
2025-03-08T08:43:15Z
2025-03-08T08:43:15Z
<![CDATA[V019plus.熊言熊语：渴望寻求共识的多癌种早筛]]>
https://newsletter.kaopubear.top/p/v019plus-bear-speech-desire-for-consensus-in-multi-cancer-early-screening#8335
思考问题的熊
2025-03-08T08:43:10Z
2025-03-08T08:43:10Z
<![CDATA[V018plus.熊言熊语：biomarker系列-同源重组修复缺陷HRD (part3 产品总览)]]>
https://newsletter.kaopubear.top/p/v018plus-biomarker-series-homologous-recombination-repair-defects-hrd-part3-product-overview#8334
思考问题的熊
2025-03-08T08:42:56Z
2025-03-08T08:42:56Z
<![CDATA[V017plus.熊言熊语：biomarker系列-同源重组修复缺陷HRD (part2 临床验证)]]>
https://newsletter.kaopubear.top/p/v017plus-bear-speak-biomarker-series-homologous-recombination-repair-deficiency-hrd-part2-clinical-validation#8333
思考问题的熊
2025-03-08T08:42:48Z
2025-03-08T08:42:48Z
<![CDATA[V013.熊言熊语：多研究些问题 少谈些逻辑]]>
https://newsletter.kaopubear.top/p/v013-bear-say-bear-speak-more-research-problems-less-talk-logic#8332
思考问题的熊
2025-03-08T08:42:47Z
2025-03-08T08:42:47Z
<![CDATA[V012.熊言熊语：当面的赞美和背地的批评都不要当真]]>
https://newsletter.kaopubear.top/p/v012-bear-words-dont-take-praise-criticism-seriously#8330
思考问题的熊
2025-03-08T08:42:43Z
2025-03-08T08:42:43Z
<![CDATA[Bonus.熊言熊语线上茶话会第一期邀请函]]>
https://newsletter.kaopubear.top/p/bonus-xiong-yan-xiong-yu-online-tea-chat-first-invitation#8331
思考问题的熊
2025-03-08T08:42:47Z
2025-03-08T08:42:47Z
<![CDATA[V016plus.熊言熊语：biomarker系列-同源重组修复缺陷 HRD (part1 从无到有)]]>
https://newsletter.kaopubear.top/p/v016plus-biomarker-series-hrd-part1#8329
思考问题的熊
2025-03-08T08:42:34Z
2025-03-08T08:42:34Z
<![CDATA[V015plus.熊言熊语：聊肿瘤生物标志物时我们在聊什么]]>
https://newsletter.kaopubear.top/p/v015plus-yunyan-yunyu-tumor-biomarkers-discussion#8328
思考问题的熊
2025-03-08T08:42:31Z
2025-03-08T08:42:31Z
<![CDATA[V014plus.熊言熊语：从靶向治疗耐药机制到联合用药策略（下篇）]]>
https://newsletter.kaopubear.top/p/v014plus-bear-sayings-targeted-therapy-resistance-mechanism-combination-therapy-strategy-part-2#8327
思考问题的熊
2025-03-08T08:42:21Z
2025-03-08T08:42:21Z
<![CDATA[V013plus.熊言熊语：从新闻稿引申到多癌种早筛公司和FDA突破性设备计划]]>
https://newsletter.kaopubear.top/p/v013plus-bear-talks-from-press-release-to-multi-cancer-early-screening-company-and-fda-breakthrough-devices-program#8326
思考问题的熊
2025-03-08T08:42:17Z
2025-03-08T08:42:17Z
<![CDATA[V011.熊言熊语：混乱和坚持的2022，困难和勇敢的2023]]>
https://newsletter.kaopubear.top/p/v011-bear-talk-confusion-and-persistence-2022-difficulties-and-courage-2023#8325
思考问题的熊
2025-03-08T08:42:16Z
2025-03-08T08:42:16Z
<![CDATA[V012plus.熊言熊语：从靶向治疗耐药机制到联合用药策略（上篇）]]>
https://newsletter.kaopubear.top/p/v012plus-bear-talk-targeted-therapy-resistance-mechanisms-combination-therapy-strategies-part-1#8324
思考问题的熊
2025-03-08T08:42:02Z
2025-03-08T08:42:02Z
<![CDATA[V010.熊言熊语：离别、陪伴和不确定性]]>
https://newsletter.kaopubear.top/p/v010-bear-words-farewell-companionship-uncertainty#8323
思考问题的熊
2025-03-08T08:42:02Z
2025-03-08T08:42:02Z
<![CDATA[V011plus.熊言熊语：2022年肿瘤精准治疗进展回顾]]>
https://newsletter.kaopubear.top/p/v011plus-bear-talk-2022-tumor-precision-treatment-progress-review#8322
思考问题的熊
2025-03-08T08:41:54Z
2025-03-08T08:41:54Z
<![CDATA[V010plus.熊言熊语：行业新人如何构建知识体系 aka 会员计划详解]]>
https://newsletter.kaopubear.top/p/v010plus-bear-sayings-how-industry-newcomers-build-knowledge-system-membership-plan-explained#8321
思考问题的熊
2025-03-08T08:41:53Z
2025-03-08T08:41:53Z
<![CDATA[熊言熊语付费会员专属微信群 欢迎你加入]]>
https://newsletter.kaopubear.top/p/bear-say-bear-chat-paid-member-exclusive-wechat-group-welcome-to-join#8320
思考问题的熊
2025-03-08T08:41:53Z
2025-03-08T08:41:53Z
<![CDATA[V009.熊言熊语：聊聊恢复更新与计划]]>
https://newsletter.kaopubear.top/p/v009-bear-talks-discuss-recovery-updates-and-plans#8319
思考问题的熊
2025-03-08T08:41:51Z
2025-03-08T08:41:51Z